title

The Syneos Health Podcast

Jeffrey Stewart

0
Followers
0
Plays
The Syneos Health Podcast
The Syneos Health Podcast

The Syneos Health Podcast

Jeffrey Stewart

0
Followers
0
Plays
OVERVIEWEPISODESYOU MAY ALSO LIKE

Details

About Us

Latest Episodes

Medical Affairs Series, Part Four: Medical Affairs in the Field

The Medical Science Liaison (MSL) has gone through a bit of an identity overhaul. A role that used to lean almost exclusively on scientific acumen must now more than ever also rely on business chops and people skills. A shift akin to moving from Geek Squad…to Apple Genius Bar.Keith Morris, Executive Managing Director, Medical Affairs at Syneos Health Consulting, and Ric Phipps, Senior Vice President, Global Field Medical Affairs for Syneos Health Deployment Solutions discuss the increased complexity of the role of as the needs of today’s customer groups are evolving and how, as a result, the required competencies and skillsets of these field teams have changed.For more episodes on Medical Affairs:Medical Affairs from ZeroMA “Squared”: Medical Affairs Meets Market AccessMedical Affairs Series, Part One – A Foundation for Medical AffairsMedical Affairs Series, Part Two – Measuring the Unmeasurable: Medical Affairs MetricsMedical Affairs Series, Part Three – Moving to the LeftLike what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

19 MIN3 w ago
Comments
Medical Affairs Series, Part Four: Medical Affairs in the Field

Medical Affairs Series, Part Three: Moving to the Left

Traditionally, Medical Affairs has served as a support function in later phases of product development, but they now need to play a more strategic and value-based role within the organization – and that means earlier and deeper engagement.In part three of our Medical Affairs Series, Suma Ramadas, Senior Managing Director and Colin Oliver, Director in Medical Affairs at Syneos Health Consulting, discuss how and why Medical Affairs organizations need to be involved earlier in the development life cycle.Be sure to check out our other Medical Affairs-related episodes:Medical Affairs from ZeroMA “Squared”: Medical Affairs Meets Market AccessMedical Affairs Series, Part One – A Foundation for Medical AffairsMedical Affairs Series, Part Two – Measuring the Unmeasurable: Medical Affairs MetricsLike what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

12 MINNOV 6
Comments
Medical Affairs Series, Part Three: Moving to the Left

Advocacy Archetypes

Patients have been at the forefront of many of healthcare’s most historic moments—not just as subjects, but also as catalysts for change. Some of today’s advocates look to the early ACT UP years for inspiration; others turn to blueprints established by pioneers like Abbey Meyers or Kathy Guisti.In this episode, Keri McDonough, Lead, Advocacy and Patient Relations at Syneos Health, explores how certain patient advocate archetypes – the Caregiver, the Creator, the Citizen, the Magician, and the Rebel – have emerged over time and dig into how social determinants of health, politics of representation and even climate change will influence the advocates of the future.For more on advocacy, check out the following publications:How Patient Advocacy Connectivity Fuels Launch SuccessThe Changing Role of Patient AdvocacyNavigating Your Local Advocacy CommunityLike what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on ...

32 MINOCT 24
Comments
Advocacy Archetypes

Medical Affairs Series, Part Two - Measuring the Unmeasurable: Medical Affairs Metrics

No industry standard currently exists to measure value and impact of medical affairs, and the traditional metrics that companies often use to determine return on investment (ROI) simply don’t apply.In this second episode in our Medical Affairs series, Josh Samon, Managing Director and Colin Oliver, Director in Medical Affairs at Syneos Health Consulting, discuss the unique challenges around defining value, and define a path forward toward creating an industry standard that truly reflects the contributions of the Medical Affairs function.Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

14 MINOCT 9
Comments
Medical Affairs Series, Part Two - Measuring the Unmeasurable: Medical Affairs Metrics

Why We Resist

Why do people make good (and bad) decisions about their health? How can we help motivate them to change and give them the resilience to try and try again? Our industry and our world are obsessed with those questions right now.Kathleen Starr, PhD, Managing Director, Behavioral Insights and Leigh Householder, Executive Vice President and Managing Director, Insights and Innovation at Syneos Health, tackle these tough questions in their new book, Why We Resist. In this episode, they talk about key principles of influence on behavior (things we all have in common), the behavioral science of segmentation (what makes us different), and how healthcare communicators can apply this knowledge to move their customers from a position of resistance to one of activation.For a deeper dive into new ways to design communications, interventions and programs to help people make better, more confident decisions about their health, check out Why We Resist, available at Amazon and other retailers. All pro...

20 MINSEP 25
Comments
Why We Resist

Medical Affairs Series, Part One: A Foundation for Medical Affairs

Medical Affairs, once considered a support function, now has a seat at the table as one of the major pillars of biopharmaceutical organizations. So now what? Our new Medical Affairs series, which will unfold over the next several months, will explore what’s next and provide insights and best practices for “Next Gen” Medical Affairs.In this first episode of the series, Suma Ramadas, Senior Managing Director in the Scientific and Medical Affairs Advisory Group for Syneos Health Consulting, sets the foundation for discussion around the Medical Affairs function, how it can continue to communicate its worth, work effectively with Clinical and Commercial functions, and develop efficient processes – beginning earlier in development – that propel commercial planning and drive greater asset value.Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

10 MINSEP 11
Comments
Medical Affairs Series, Part One: A Foundation for Medical Affairs

A Regulatory Roadmap for Real World Evidence

The need for real world evidence is growing beyond its original footprint of post-market intelligence, with uses now including regulatory approval, proof of value, maximized access and more. However, without a true understanding of the regulatory requirements around real world evidence, there is a risk of a “Goldilocks effect”— gathering either not enough information, the wrong information, or far more information than they need.Stuart McCully, PhD, Vice President and Tara Isherwood, Senior Director, Real World Clinical Consulting, discuss the key information developers need in order to plan studies that will get them the intel that they need, the right way.For more on real world evidence from across Syneos Health, check out our interviews with Alastair MacDonald in Episode 31, and Dave Thompson in Episode 1.Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syn...

19 MINAUG 28
Comments
A Regulatory Roadmap for Real World Evidence

Talented Teams

Creating and supporting productive, motivated and happy teams is an ongoing challenge in today’s global workplace – and particularly in the fast-paced biopharmaceutical marketplace. Incentives can differ based on region, culture, or individual. Approaches can hinge on countless variables beyond compensation – although in some cases, cash is king. So what’s the key to success?Based on 25 years of experience developing clinical teams, Tara Fitzgerald, President, Clinical Development Services at Syneos Health, shares her philosophy on attracting, building and retaining top talent – and what it truly takes to lead.Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

19 MINAUG 14
Comments
Talented Teams

Digital Therapeutics

There are dozens of software-driven products under regulatory review for diagnosing, treating, or preventing medical conditions, defining an entirely new sector for the life sciences industry.Today we are joined by Allison Murphy, Vice President, Business Development, Selling Solutions at Syneos Health and Skye Hodson, PhD, Engagement Manager, Commercial Advisory Group at Syneos Health Consulting, to discuss the digital therapeutics landscape, the opportunities for both biopharma and tech companies, regulatory and payer hurdles, and more.For a deeper dive, download our report, How Digital Therapeutics Developers Can Satisfy Diverse Stakeholder Needs.To become part of the broader conversation, check out these organizations mentioned in this episode: Digital Therapeutics Alliance and Digital Medicine Society (DiMe).Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@s...

19 MINJUL 31
Comments
Digital Therapeutics

Talking About PIE

Not that kind of pie. In this case, PIE – or Preapproval Information Exchange – refers to the communication of clinical and health care economic information on therapies in development between U.S. population health decision makers and drug manufacturers prior to regulatory approval. John Seay, Vice President and Content Expert, Managed Markets Communications at Syneos Health, discusses the benefits of PIE, best practices for entering into these discussions, and the importance of building advocacy with payer organizations as a means of maximizing access.For more information, check out the Food and Drug Administration guidance for PIE published in June 2018.Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

23 MINJUL 17
Comments
Talking About PIE

Latest Episodes

Medical Affairs Series, Part Four: Medical Affairs in the Field

The Medical Science Liaison (MSL) has gone through a bit of an identity overhaul. A role that used to lean almost exclusively on scientific acumen must now more than ever also rely on business chops and people skills. A shift akin to moving from Geek Squad…to Apple Genius Bar.Keith Morris, Executive Managing Director, Medical Affairs at Syneos Health Consulting, and Ric Phipps, Senior Vice President, Global Field Medical Affairs for Syneos Health Deployment Solutions discuss the increased complexity of the role of as the needs of today’s customer groups are evolving and how, as a result, the required competencies and skillsets of these field teams have changed.For more episodes on Medical Affairs:Medical Affairs from ZeroMA “Squared”: Medical Affairs Meets Market AccessMedical Affairs Series, Part One – A Foundation for Medical AffairsMedical Affairs Series, Part Two – Measuring the Unmeasurable: Medical Affairs MetricsMedical Affairs Series, Part Three – Moving to the LeftLike what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

19 MIN3 w ago
Comments
Medical Affairs Series, Part Four: Medical Affairs in the Field

Medical Affairs Series, Part Three: Moving to the Left

Traditionally, Medical Affairs has served as a support function in later phases of product development, but they now need to play a more strategic and value-based role within the organization – and that means earlier and deeper engagement.In part three of our Medical Affairs Series, Suma Ramadas, Senior Managing Director and Colin Oliver, Director in Medical Affairs at Syneos Health Consulting, discuss how and why Medical Affairs organizations need to be involved earlier in the development life cycle.Be sure to check out our other Medical Affairs-related episodes:Medical Affairs from ZeroMA “Squared”: Medical Affairs Meets Market AccessMedical Affairs Series, Part One – A Foundation for Medical AffairsMedical Affairs Series, Part Two – Measuring the Unmeasurable: Medical Affairs MetricsLike what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

12 MINNOV 6
Comments
Medical Affairs Series, Part Three: Moving to the Left

Advocacy Archetypes

Patients have been at the forefront of many of healthcare’s most historic moments—not just as subjects, but also as catalysts for change. Some of today’s advocates look to the early ACT UP years for inspiration; others turn to blueprints established by pioneers like Abbey Meyers or Kathy Guisti.In this episode, Keri McDonough, Lead, Advocacy and Patient Relations at Syneos Health, explores how certain patient advocate archetypes – the Caregiver, the Creator, the Citizen, the Magician, and the Rebel – have emerged over time and dig into how social determinants of health, politics of representation and even climate change will influence the advocates of the future.For more on advocacy, check out the following publications:How Patient Advocacy Connectivity Fuels Launch SuccessThe Changing Role of Patient AdvocacyNavigating Your Local Advocacy CommunityLike what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on ...

32 MINOCT 24
Comments
Advocacy Archetypes

Medical Affairs Series, Part Two - Measuring the Unmeasurable: Medical Affairs Metrics

No industry standard currently exists to measure value and impact of medical affairs, and the traditional metrics that companies often use to determine return on investment (ROI) simply don’t apply.In this second episode in our Medical Affairs series, Josh Samon, Managing Director and Colin Oliver, Director in Medical Affairs at Syneos Health Consulting, discuss the unique challenges around defining value, and define a path forward toward creating an industry standard that truly reflects the contributions of the Medical Affairs function.Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

14 MINOCT 9
Comments
Medical Affairs Series, Part Two - Measuring the Unmeasurable: Medical Affairs Metrics

Why We Resist

Why do people make good (and bad) decisions about their health? How can we help motivate them to change and give them the resilience to try and try again? Our industry and our world are obsessed with those questions right now.Kathleen Starr, PhD, Managing Director, Behavioral Insights and Leigh Householder, Executive Vice President and Managing Director, Insights and Innovation at Syneos Health, tackle these tough questions in their new book, Why We Resist. In this episode, they talk about key principles of influence on behavior (things we all have in common), the behavioral science of segmentation (what makes us different), and how healthcare communicators can apply this knowledge to move their customers from a position of resistance to one of activation.For a deeper dive into new ways to design communications, interventions and programs to help people make better, more confident decisions about their health, check out Why We Resist, available at Amazon and other retailers. All pro...

20 MINSEP 25
Comments
Why We Resist

Medical Affairs Series, Part One: A Foundation for Medical Affairs

Medical Affairs, once considered a support function, now has a seat at the table as one of the major pillars of biopharmaceutical organizations. So now what? Our new Medical Affairs series, which will unfold over the next several months, will explore what’s next and provide insights and best practices for “Next Gen” Medical Affairs.In this first episode of the series, Suma Ramadas, Senior Managing Director in the Scientific and Medical Affairs Advisory Group for Syneos Health Consulting, sets the foundation for discussion around the Medical Affairs function, how it can continue to communicate its worth, work effectively with Clinical and Commercial functions, and develop efficient processes – beginning earlier in development – that propel commercial planning and drive greater asset value.Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

10 MINSEP 11
Comments
Medical Affairs Series, Part One: A Foundation for Medical Affairs

A Regulatory Roadmap for Real World Evidence

The need for real world evidence is growing beyond its original footprint of post-market intelligence, with uses now including regulatory approval, proof of value, maximized access and more. However, without a true understanding of the regulatory requirements around real world evidence, there is a risk of a “Goldilocks effect”— gathering either not enough information, the wrong information, or far more information than they need.Stuart McCully, PhD, Vice President and Tara Isherwood, Senior Director, Real World Clinical Consulting, discuss the key information developers need in order to plan studies that will get them the intel that they need, the right way.For more on real world evidence from across Syneos Health, check out our interviews with Alastair MacDonald in Episode 31, and Dave Thompson in Episode 1.Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syn...

19 MINAUG 28
Comments
A Regulatory Roadmap for Real World Evidence

Talented Teams

Creating and supporting productive, motivated and happy teams is an ongoing challenge in today’s global workplace – and particularly in the fast-paced biopharmaceutical marketplace. Incentives can differ based on region, culture, or individual. Approaches can hinge on countless variables beyond compensation – although in some cases, cash is king. So what’s the key to success?Based on 25 years of experience developing clinical teams, Tara Fitzgerald, President, Clinical Development Services at Syneos Health, shares her philosophy on attracting, building and retaining top talent – and what it truly takes to lead.Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

19 MINAUG 14
Comments
Talented Teams

Digital Therapeutics

There are dozens of software-driven products under regulatory review for diagnosing, treating, or preventing medical conditions, defining an entirely new sector for the life sciences industry.Today we are joined by Allison Murphy, Vice President, Business Development, Selling Solutions at Syneos Health and Skye Hodson, PhD, Engagement Manager, Commercial Advisory Group at Syneos Health Consulting, to discuss the digital therapeutics landscape, the opportunities for both biopharma and tech companies, regulatory and payer hurdles, and more.For a deeper dive, download our report, How Digital Therapeutics Developers Can Satisfy Diverse Stakeholder Needs.To become part of the broader conversation, check out these organizations mentioned in this episode: Digital Therapeutics Alliance and Digital Medicine Society (DiMe).Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@s...

19 MINJUL 31
Comments
Digital Therapeutics

Talking About PIE

Not that kind of pie. In this case, PIE – or Preapproval Information Exchange – refers to the communication of clinical and health care economic information on therapies in development between U.S. population health decision makers and drug manufacturers prior to regulatory approval. John Seay, Vice President and Content Expert, Managed Markets Communications at Syneos Health, discusses the benefits of PIE, best practices for entering into these discussions, and the importance of building advocacy with payer organizations as a means of maximizing access.For more information, check out the Food and Drug Administration guidance for PIE published in June 2018.Like what you’re hearing? Be sure to rate and review us! We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

23 MINJUL 17
Comments
Talking About PIE
hmly
himalayaプレミアムへようこそ聴き放題のオーディオブックをお楽しみください。